Edwards Lifesciences executive Lippis sells 619 shares

The exercise and sale were made under a Rule 10b5-1 trading plan adopted February 13, 2026.

Available on EDGAR 11/10/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised options for 619 shares of common stock on November 10, 2026, at an exercise price of $72.68 per share, then sold those 619 shares at $104.25 per share. The option position was reported as 2,476 shares after the exercise. The transactions were made under a Rule 10b5-1 trading plan adopted February 13, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 619 shares ($20K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 619 shs ($65K)

Approx. gross sale proceeds $65K

Approx. exercise cost $45K

Approx. pre-tax spread $20K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	619	$0.00	$0.00
Exercise	Common Stock F1	619	$72.68	$45K
Sale	Common Stock F1	619	$104.25	$65K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 2,476 options (Direct); Common Stock — 40,033.9103 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Key Figures

Options exercised: 619 shares Exercise price: $72.68 per share Shares sold: 619 shares +2 more

5 metrics

Options exercised 619 shares November 10, 2026

Exercise price $72.68 per share Options exercised November 10, 2026

Shares sold 619 shares November 10, 2026

Sale price $104.25 per share Sale on November 10, 2026

Option position after exercise 2,476 shares Reported after the November 10, 2026 exercise

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Acquire) financial

"Employee Stock Option (Right to Acquire)"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EW shares did Daniel J. Lippis sell and at what price?

Daniel J. Lippis sold 619 shares of common stock at $104.25 per share on November 10, 2026.

How many EW options did Daniel J. Lippis exercise?

Daniel J. Lippis exercised options for 619 shares of common stock at an exercise price of $72.68 per share on November 10, 2026; the option position was reported as 2,476 shares afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2026		M(1)		619	A	$72.68	40,652.9103	D
Common Stock	11/10/2026		S(1)		619	D	$104.25	40,033.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$72.68	11/10/2026		M			619	05/07/2021	05/06/2027	Common Stock	619	$0.0000	2,476	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)